Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 319

Sort by

Sort Order Select

Journal Articles

Predicting CAR T-cell therapy outcomes in large B-cell lymphoma using pre-infusion clinical and inflammatory markers: A machine learning approach with explainable artificial intelligence

Blood (2025) 146 (Supplement 1): 2569.

https://doi.org/10.1182/blood-2025-2569

Published: 2025

Journal Articles

Integrated multi-omic profiling identifies molecular subtypes and predicts outcomes in newly diagnosed peripheral T-cell lymphomas

Blood (2025) 146 (Supplement 1): 1758.

https://doi.org/10.1182/blood-2025-1758

Published: 2025

Journal Articles

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study

Blood (2025) 146 (Supplement 1): 7636.

https://doi.org/10.1182/blood-2025-7636

Published: 2025

Journal Articles

Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis

Blood (2025) 146 (Supplement 1): 5510.

https://doi.org/10.1182/blood-2025-5510

Published: 2025

Journal Articles

Older age and complex karyotype are the main predictors of mortality irrespective of allogeneic transplant in therapy-related myeloid neoplasms: A single‑center retrospective cohort

Maria Chiara Di Chio, Emanuele Guido, Angelica Barone, Jenny Mantovani, Silva Ljevar, Chiara Bonini, Antonella Aiello, Valentina Monti, Daniele Lorenzini, Lucia Farina, Martina Pennisi, Paolo Corradini

Blood (2025) 146 (Supplement 1): 5161.

https://doi.org/10.1182/blood-2025-5161

Published: 2025

Journal Articles

Checkpoint inhibitors exposure does not affect survival and safety in PMBCL patients receiving CAR T-cells therapy: An analysis of the italian CART-SIE study

Blood (2025) 146 (Supplement 1): 5502.

https://doi.org/10.1182/blood-2025-5502

Published: 2025

Journal Articles

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

Blood (2025) 146 (Supplement 1): 3722.

https://doi.org/10.1182/blood-2025-3722

Published: 2025

Journal Articles

Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study

Blood (2025) 146 (Supplement 1): 3721.

https://doi.org/10.1182/blood-2025-3721

Published: 2025

Journal Articles

Adding selinexor to ifosfamide, etoposide and desametasone does not improve the outcome in relapsed and refractory peripheral T-cell lymphomas: First report of phase II S-ide study.

Annalisa Chiappella, Anna Dodero, Alessandro Re, Claudia Castellino, Grazia Mallia, Silva Ljevar, Laura Arletti, Luca Arcaini, Pellegrino Musto, Anna Guidetti, Rosalba Miceli, Anisa Bermema, Cristiana Carniti, Paolo Corradini

Blood (2025) 146 (Supplement 1): 1868.

https://doi.org/10.1182/blood-2025-1868

Published: 2025

Journal Articles

Health-related quality of life trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy: Results from a prospective observational study

Blood (2025) 146 (Supplement 1): 6279.

https://doi.org/10.1182/blood-2025-6279

Published: 2025

Journal Articles

The prognostic value of patient-reported fatigue for survival in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy

Blood (2025) 146 (Supplement 1): 6278.

https://doi.org/10.1182/blood-2025-6278

Published: 2025

Journal Articles

Frontline nilotinib vs dasatinib in newly diagnosed chronic phase chronic myeloid leukemia: A propensity score analysis based on AIFA monitoring registries

Massimo Breccia, Pier Paolo Olimpieri, Fabrizio Pane, Simone Celant, Alessandra Iurlo, Valentina Summa, Paolo Corradini, Pier Luigi Zinzani, Pierluigi Russo

Blood (2025) 146 (Supplement 1): 3774.

https://doi.org/10.1182/blood-2025-3774

Published: 2025

Journal Articles

Integrated clinical and radiomic PET-FLIPI score for risk stratification in newly diagnosed follicular lymphoma

Blood (2025) 146 (Supplement 1): 3561.

https://doi.org/10.1182/blood-2025-3561

Published: 2025

Journal Articles

Long term follow up of the response adapted FOLL12 trial for patients with advanced stage follicular lymphoma: A study by the fondazione italiana linfomi (FIL).

Blood (2025) 146 (Supplement 1): 1004.

https://doi.org/10.1182/blood-2025-1004

Published: 2025

Journal Articles

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis

Blood (2025) 146 (8): 1011–1029.

https://doi.org/10.1182/blood.2024027197

Published: 2025

Includes: Supplemental data

Journal Articles

Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study

Michel Delforge, Joshua Richter, Yael C. Cohen, Paolo Corradini, Douglas W Sborov, Alexander M. Lesokhin, Jesus G Berdeja, Moshe E Gatt, Laura Paris, Laura Rosinol Dachs, Hang Quach, Manisha Kanwar, Olivier Catalani, Paresh Sewpaul, Elisabeth Wassner-Fritsch, Ameet Mishra, Kerstin Trunzer, Shaji Kumar

Blood (2024) 144 (Supplement 1): 4732.

https://doi.org/10.1182/blood-2024-199519

Published: 2024

Journal Articles

Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

Blood (2024) 144 (Supplement 1): 4362.

https://doi.org/10.1182/blood-2024-203004

Published: 2024

Journal Articles

High Ferritin and C-Reactive Protein Levels Result in Poor Clinical Outcome in R/R Large B-Cell Lymphoma Patients Despite Significant Anti-CD19 CAR-T Cell In Vivo Expansion

Blood (2024) 144 (Supplement 1): 4786.

https://doi.org/10.1182/blood-2024-201399

Published: 2024

Journal Articles

Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Blood (2024) 144 (Supplement 1): 674.

https://doi.org/10.1182/blood-2024-197908

Published: 2024

Journal Articles

Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

Blood (2024) 144 (Supplement 1): 988.

https://doi.org/10.1182/blood-2024-194328

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Predicting CAR T-cell therapy outcomes in large B-cell lymphoma using pre-infusion clinical and inflammatory markers: A machine learning approach with explainable artificial intelligence

Integrated multi-omic profiling identifies molecular subtypes and predicts outcomes in newly diagnosed peripheral T-cell lymphomas

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study

Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis

Older age and complex karyotype are the main predictors of mortality irrespective of allogeneic transplant in therapy-related myeloid neoplasms: A single‑center retrospective cohort

Checkpoint inhibitors exposure does not affect survival and safety in PMBCL patients receiving CAR T-cells therapy: An analysis of the italian CART-SIE study

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study

Adding selinexor to ifosfamide, etoposide and desametasone does not improve the outcome in relapsed and refractory peripheral T-cell lymphomas: First report of phase II S-ide study.

Health-related quality of life trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy: Results from a prospective observational study

The prognostic value of patient-reported fatigue for survival in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy

Frontline nilotinib vs dasatinib in newly diagnosed chronic phase chronic myeloid leukemia: A propensity score analysis based on AIFA monitoring registries

Integrated clinical and radiomic PET-FLIPI score for risk stratification in newly diagnosed follicular lymphoma

Long term follow up of the response adapted FOLL12 trial for patients with advanced stage follicular lymphoma: A study by the fondazione italiana linfomi (FIL).

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis

Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study

Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

High Ferritin and C-Reactive Protein Levels Result in Poor Clinical Outcome in R/R Large B-Cell Lymphoma Patients Despite Significant Anti-CD19 CAR-T Cell In Vivo Expansion

Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only